Clinical significance of measurements of serum CA19-9 in genitourinary cancer.
- Author:
Heon Joong KANG
1
;
Jong Chul KIM
;
Hyun Yul RHEW
Author Information
1. Departmet of Urology, Kosin Medical College, Pusan Korea.
- Publication Type:Original Article
- Keywords:
CA19-9;
Genitourinary tract tumor
- MeSH:
Carcinoma, Renal Cell;
Gastrointestinal Tract;
Male;
Mass Screening;
Neoplasm Metastasis;
Penile Neoplasms;
Prognosis;
Sensitivity and Specificity;
Testicular Neoplasms;
Urinary Bladder;
Urinary Bladder Neoplasms;
Urogenital Neoplasms*
- From:Korean Journal of Urology
1993;34(3):409-413
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We measured serum CA19-9 from March 1990 to June 1992 in 63 cases of normal controls, 56 cases or bladder cancer, 32 cases of renal cell carcinoma, 8 cases of prostatic carcinoma, 4 cases of penile cancer. 2 cases of testicular cancer and 3 cases of carcinoma of gastrointestinal tract with metastasis to the retroperitoneum. The results of this study were that serum levels of CA19-9 in urinary bladder cancer, renal cell carcinoma and prostatic carcinoma were statistically significant. However, sensitivity was low, 14. 29% for urinary bladder cancer, 18.75% for renal cell carcinoma. 12.5 % for prostatic carcinoma and specificity was 95.2%. In renal cell carcinoma, there was no change in serum level between stages. However there was a statistically significant difference (p<0.05) between low stage(A, B) and high stage(C, D) urinary cancers. We suggest that serum CA19-9 levels cannot be used as a screening test or prognosis indicator in tumors of the genitourinary tract ; however it can be helpful in differentiating between low and high stage urinary bladder cancers.
